Close, but no cigar: Biosimilar products and firm regulatory stance
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Healthcare Management"
DOI: 10.1080/20479700.2020.1736790
Abstract: ABSTRACT The medical and pharmaceutical industries must commit to full consensus on biosimilar products. Regulatory recommendations and current resources applied to biosimilars should not be squandered. Additionally, continued lessons learned should be applied for the… read more here.
Keywords: biosimilar; firm regulatory; cigar biosimilar; products firm ... See more keywords